NASDAQ · Drug Manufacturers - Specialty & Generic

ORGO (ORGO) Stock

$2.40 -4.56% NASDAQ: ORGO Healthcare

Valuation

MetricValue
Price$2.40
Market Cap$309.46M
P/E Ratio16.07
P/B Ratio0.71
P/S Ratio0.61
EPS (TTM)$0.15
52-Week High$7.08
52-Week Low$2.04
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE8.53%
ROA6.18%
ROCE12.90%
Gross Margin9.95%
Operating Margin9.95%
Net Margin-0.06%
Debt/Equity0.19
Current Ratio3.62

Annual Financials (USD)

Metric20212022202320242025
Revenue$467.0M$451.0M$433.0M$482.0M$563.0M
Operating Profit$72.0M$22.0M$13.0M$-1.0M$56.0M
Net Profit$94.0M$16.0M$5.0M$1.0M$37.0M
EPS$0.70$0.12$0.04$-0.01$0.15
Op Margin15.4%5.0%2.9%-0.3%9.9%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$443.0M$449.0M$460.0M$498.0M$599.0M
Total Liabilities$202.0M$184.0M$181.0M$113.0M$165.0M
Cash$114.0M$102.0M$104.0M$136.0M$94.0M
Borrowings$132.0M$124.0M$119.0M$43.0M$133.0M

Latest News

Organogenesis Holdings Inc. to Report Second Quarter of Fiscal Year 2026 Financial Results on August 6, 2026 GlobeNewswire · Jul 9, 2026 Organogenesis Announces FDA Acceptance of Biologics License Application for ReNu® for the Management of Symptomatic Knee Osteoarthritis GlobeNewswire · Jul 6, 2026 Is Organogenesis Holdings Inc. (ORGO) Losing Momentum? BTIG Pulls Buy Rating After Q1 Update Insider Monkey · May 20, 2026 Spotlight On Penny Stocks To Consider In May 2026 Simply Wall St. · May 14, 2026 Undervalued Small Caps With Insider Buying To Watch In May 2026 Simply Wall St. · May 14, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$62.0M$25.0M$31.0M$14.0M$-10.0M
Investing Cash Flow$-62.0M$-68.0M$-49.0M$-20.0M$-28.0M
Financing Cash Flow$-1.0M$1.0M$0$-24.0M$-16.0M
Net Cash Flow$30.0M$-11.0M$1.0M$32.0M$-42.0M
Free Cash Flow$31.0M$-9.0M$7.0M$4.0M$-24.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA4.21
FCF Yield5.43%
Quick Ratio3.16
Interest Coverage—
Return 1Y-51.20%
Return 3Y-41.45%
Return 5Y-85.16%

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ANGO $14.63 +2.02% -14.36 $604.69M 0.00%
BCYCBicycle Therapeutics plc $4.22 +0.24% -1.34 $292.84M 0.00%
CMPX $1.89 -4.55% -4.71 $340.37M 0.00%
EBS $7.16 -1.45% 8.67 $369.17M 0.00%
EOLS $6.03 -3.05% -9.25 $397.10M 0.00%

About ORGO

ORGO is led by CEO Gary S. Gillheeney, employs 869 people, headquartered in US, publicly traded since 2017.

ORGO stock trades at $2.40 with a market capitalization of $309.46M. The stock is valued at a price-to-earnings (P/E) ratio of 16.07, price-to-book of 0.71, price-to-sales of 0.61. Over the past 52 weeks the stock has ranged between $2.04 and $7.08, and currently trades 66.1% below its 52-week high.

On profitability, ORGO generates a return on equity (ROE) of 8.53%, return on capital employed of 12.90%, an operating margin of 9.95%, a net profit margin of -0.06%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides